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OBJECTIVES This study examined the outcomes of new-onset heart failure (HF) outpatients managed by
cardiologists and primary care (PC) physicians.
BACKGROUND Several studies have sought differences in outcomes between patients with HF managed by
cardiologists and PC physicians, but most focused on inpatients, who often represent later
stages of HF, whereas many treatments have their impact by delaying disease progression.
METHODS This was a retrospective cohort study of incident HF identified between 1996 and 1997 in a
staff model health maintenance organization. Cardiology care was defined as 2 visits or
25% of total medical outpatient visits to cardiology. Records from a cohort of 403 patients
with new-onset outpatient HF were reviewed. The main outcome measure was a combination
of death and/or cardiovascular hospitalization at 24 months.
RESULTS Cardiologists’ patients (n  198) were younger (66 vs. 71 years, p  0.001), were more likely
men (54% vs. 46%, p 0.01), had coronary artery disease (64% vs. 42%, p 0.001), and had
a low (45%) ejection fraction (EF) (66% vs. 44%, p 0.001) compared with PC physicians’
patients. More cardiologists’ patients received an EF assessment (94% vs. 74%, p  0.001),
angiotensin-converting enzyme inhibitors (83% vs. 68%, p  0.001), and beta-blockers (38%
vs. 22%, p  0.001). In multivariate proportional hazards modeling that included variables
that differed between providers and univariate predictors of outcomes, cardiology care was an
independent predictor of a lower risk for the combined outcome (hazard ratio 0.62,
confidence interval 0.42 to 0.93, p  0.02).
CONCLUSIONS Cardiology care at this early stage of HF is associated with improved guideline adherence and
a reduced risk of the composite outcome of death plus cardiovascular hospitalization. (J Am
Coll Cardiol 2003;41:62–8) © 2003 by the American College of Cardiology Foundation
Despite recent advances in therapy, such as angiotensin-
converting enzyme (ACE) inhibitors and beta-blockers,
patients with chronic heart failure (HF) continue to expe-
rience high mortality and morbidity rates, resulting in
five-year survival rates in the community below 50% and
approximately one million hospitalizations each year in the
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U.S. (1–3). Heart failure is one of the few cardiovascular
conditions increasing in prevalence, approaching five mil-
lion patients in the U.S., and is also the second most
frequent cardiovascular reason (after hypertension) for out-
patient physician visits. Primary care (PC) providers manage
the majority of patients with HF, and one goal of some
managed care organizations has been to reduce costs by
limiting utilization of specialists in treating this common
condition.
The rapid evolution in treatment recommendations for
HF has led some to question whether specialty care might
improve outcomes for these patients. Several studies indi-
cate that cardiologists are more likely to practice in confor-
mity with guideline recommendations, but they also employ
more diagnostic tests and procedures than PC practitioners
(4–7). In the management of acute myocardial infarction
(MI), this combination of greater adherence to guidelines
and greater procedural use may be associated with better
outcomes (5,8–11), but it is less clear whether this is the
case with HF patients (6,12–14).
Prior studies of HF management and outcomes have
focused on patients who were hospitalized or referred to
specialized HF programs. Such patients are usually the most
severely affected, often representing treatment failures, and
they experience very high rate of subsequent mortality and
morbidity. At this far end of the spectrum, comparisons
between PC providers and specialists may not be appropri-
ate. In addition, hospitalized patients with HF are often
co-managed, making it difficult to distinguish contributions
of general and specialty care. As a result, it may be more
relevant and methodologically preferable to examine man-
agement practices and outcomes at earlier stages, particu-
larly because the most effective treatments for HF appear to
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exert their benefit by preventing its progression. Therefore,
we designed a retrospective cohort study to examine the
characteristics, management, and outcomes of outpatients
with new-onset HF managed by PC physicians and cardi-
ologists. This study was undertaken in a staff model health
maintenance organization (HMO) and did not involve
cardiologists specializing in HF, which enhances its rele-
vance to community practice.
METHODS
Identification of study cohort. This was a retrospective
cohort study of patients with new-onset HF conducted
within the northern California Kaiser Permanente Medical
Care Program (KPMCP). The Kaiser system has highly
developed and well-validated data management systems,
which allow identification of outpatient diagnoses, provider
specialty, and patient outcomes. The KPMCP also has a
relatively stable membership of insured patients who receive
almost all of their care at Kaiser facilities and are not
restricted in their access to cardiology specialty care. Spe-
cifically, access to specialty care is not limited by financial
incentives, policy guidelines, or the need for prior authori-
zation. We identified patients with new-onset HF managed
initially in the outpatient setting from July 1996 through
August 1997 and evaluated their treatment and outcomes
over a two-year period. This study was performed in
accordance with a research protocol approved by the insti-
tutional review board at KPMCP.
Inclusion criteria. Incident HF cases were identified from
the database by an outpatient encounter form with diagnos-
tic codes of HF (International Classification of Disease
[ICD]-9 code 428.0), cardiomyopathy (ICD-9 code 425.0),
or hypertensive heart disease with HF (ICD-9 402.1,
402.11, 402.91, 404.01, 404.3, 404.11-.15) in individuals
enrolled in the KPMCP for at least 12 months. To restrict
the cohort to patients with new-onset HF, those with a
prior primary or secondary diagnosis of a HF-related
diagnosis on a prior hospital discharge were excluded, as
were patients admitted within 24 h of their diagnosis. The
date of the first encounter was treated as the baseline date
for HF diagnosis.
We identified 8,597 potential subjects with HF during
the study window who had no prior outpatient visit with an
ICD-9 code diagnosis for HF (Fig. 1). Additional patients
were excluded because of a prior HF hospital discharge
diagnosis (n  2,941), lack of continuous enrollment in the
KPMCP (unless the patient died during the follow-up
period) (n  1,201), and the presence of prespecified
conditions thought to dominate subsequent management
and outcomes, including end-stage renal disease on hemo-
dialysis, dementia, HIV/AIDS, cirrhosis, or malignancy
other than basal cell carcinoma (n 250). Of the remaining
4,205 potential subjects, a random sample of 529 patients
was selected for thorough chart review. Of this initial
sample of patients, approximately 80% were followed by PC
physicians alone. Therefore, an additional random sample
of 165 charts of patients who were seen by any cardiologist
was included to enrich the comparison group.
The chart reviews were performed by a professional chart
reviewer with a nursing background (n  619) and by a
physician employed part time for this purpose (n  75).
Patients’ charts were reviewed for up to two years before the
first HF diagnosis, and for two years after the initial
diagnosis to examine the processes of care and clinical
outcomes. Of the 694 charts reviewed, 127 patients who
had clear evidence of preceding HF (thereby not meeting
the inclusion criterion for new-onset HF) and 17 patients
with no clinical evidence to support the computer diagnosis
of HF using Framingham criteria (15) were excluded. In
addition, during chart review, 18 patients who were found
to have one or more of the previously listed comorbid
conditions that were not listed in the diagnostic database
and 85 patients admitted within 24 h of the initial diagnosis
were also excluded. Exclusions were also made for missing
charts (n 35) and for lack of patient follow-up beyond the
first visit (n  4). A total of 403 patients remained for
analysis.
Comorbid conditions, medication use, and diagnostic test
results were extracted from chart review. Coronary artery
disease (CAD) was defined as a documented history of prior
MI, percutaneous coronary intervention, coronary artery
bypass surgery, or a cardiac catheterization showing a70%
lesion in any major artery. A medication was considered
prescribed if the provider listed the medication as a drug the
patient was taking or it was a drug that the patient was
refilling at the Kaiser pharmacy. Medication use was eval-
uated within six months after the diagnosis of HF. Labo-
ratory results were determined through a computerized
laboratory database. Deaths were identified from the chart
review and by interrogating the state of California death
registry. All hospitalizations within the Kaiser system were
reviewed. Records of outside hospitalizations, which ac-
count for approximately 10% of all hospital admissions for
KPMCP members, were available only if documented in the
chart.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
CAD  coronary artery disease
CC  cardiology care
CI  confidence interval
EF  ejection fraction
HF  heart failure
HMO  health maintenance organization
HR  hazard ratio
ICD  International Classification of Disease
KPMCP  Kaiser Permanente Medical Care Program
MI  myocardial infarction
PC  primary care
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Care classification. Before any data analysis, patients were
categorized as having cardiology care (CC) on the basis of
the number of visits to a cardiologist or the proportion of
those visits to the total number of visits to medicine
providers using these criteria:
1. More than two office visits to a cardiologist during the
follow-up period or before a first major end point (death
or cardiovascular hospitalization) if one occurred.
2. For patients with only two visits to a cardiologist, these
constituted at least 25% of the total outpatient visits to
medicine providers during the follow-up period or before
a first major end point.
3. For patients with only one visit to a cardiologist, this visit
constituted at least 50% of the total outpatient visits to
medicine providers during the follow-up period or before
a first major end point.
Patients who did not meet these definitions for CC were
classified as having PC if they had at least two visits to
internists or family practitioners. Visits to other providers
Figure 1. Derivation of heart failure cohort. CHF chronic heart failure.
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such as nurse practitioners were not counted toward the PC
visits.
Study outcomes. The prospectively defined primary end
point was the composite of death from any cause or a
hospitalization for a primary cardiovascular diagnosis, ana-
lyzed by time to first event using proportional hazards
models, with adjustment for patient characteristics that
differed between the provider groups and that showed
evidence of univariate prognostic significance. Additional
prespecified analyses were all-cause mortality and adherence
to HF guidelines developed by the Agency for Health Care
Policy and Research (16) and the American College of
Cardiology and American Heart Association (17). Guide-
line recommendations that were evaluated were assessment
of left ventricular function and use of ACE inhibitors in
patients with ejection fractions (EFs) 45% within six
months of the diagnosis of HF. Beta-blocker use was
examined but was not considered an end point because there
were no guideline recommendations for beta-blocker use
during the time period evaluated. We also compared the use
of lipid-lowering agents and antithrombotic agents in pa-
tients with associated coronary or peripheral arterial disease
and the use of anticoagulation in patients in atrial fibrilla-
tion (AF). Because patient education was not routinely
documented in the chart, it was not evaluated as a guideline
adherence measure.
Statistical analysis. All continuous data are expressed as
mean value  SD. Comparisons between care groups were
performed using t tests for continuous variables and chi-
square analyses for categorical variables. For all compari-
sons, p  0.05 was considered statistically significant.
The primary outcome of time to death or first cardiovas-
cular hospitalization was examined by Cox proportional
hazards modeling. Age, gender, and the presence of systolic
dysfunction (defined as a quantitative EF measurement
45% or a qualitative interpretation of “mild,” “moderate,”
or “severe” reduction) were prespecified for the proportional
hazards analysis. Other variables that were potential univar-
iate predictors of outcome (p  0.16) were entered stepwise
into these models. Statistical analysis was performed with an
SAS (Cary, North Carolina) database statistical software
package, version 6.12.
RESULTS
Patient characteristics. The clinical characteristics of pa-
tients classified as CC (n  198) and PC (n  205) are
shown in Table 1. The CC patients were somewhat younger
and included a higher proportion of men. They were also
more likely to have definite CAD, a history of documented
MI, and AF. The CC group had more patients with
confirmed systolic dysfunction (63% vs. 32%, p  0.0012).
Comorbid conditions, including diabetes, chronic obstruc-
tive pulmonary disease, and peripheral arterial disease, were
similarly distributed. The degree of hyponatremia, anemia,
and renal insufficiency based on serum laboratory tests
within 90 days of the HF diagnosis were not significantly
different between the two groups (Table 1).
Guideline adherence. The recommendation that left ven-
tricular function be assessed in patients with HF was
considered fulfilled if an assessment of EF was performed
within 24 months before the HF diagnosis or at anytime
during the follow-up period. In the CC group, 94% of
patients had at least one measurement of EF in the specified
time period, whereas only 74% of the PC patients had an
EF measurement (p  0.001).
As shown in Table 2, patients in the CC group were
more likely than the PC group to receive ACE inhibitors,
Table 1. Baseline Characteristics of Heart Failure Patients*
Variable
Cardiology
Care
(n  198)
Primary
Care
(n  205) p Value
Demographics
Age, (mean  SD), yrs 66  12 71  11 0.001
Male gender (%) 54.3% 45.7% 0.01
Cardiovascular disease
Mean EF (%)† 39  15 43  17 0.01
EF 45%† 125 (63) 66 (32) 0.0001
Hypertension 138 (70) 146 (71) 0.74
CAD 126 (64) 87 (42) 0.001
MI 76 (38) 59 (29) 0.041
Atrial fibrillation 51 (26) 30 (15) 0.005
CVA 32 (16) 39 (19) 0.45
PAD 34 (17) 41 (20) 0.47
Comorbid conditions
Diabetes 43 (22) 61 (30) 0.07
COPD 43 (22) 61 (30) 0.07
Creat 1.4 mg/dl‡ 31 (16) 36 (18) 0.55
Hb 12 g/dl§ 51 (26) 49 (24) 0.81
Na 135 mmol/l 10 (5) 15 (9) 0.23
ETOH abuse 27 (14) 24 (12) 0.56
Tobacco (current) 26 (13) 41 (20) 0.80
*Data are presented as number (percentage) unless otherwise indicated; †numbers
based on number of patients with measured EF (n  187 in cardiology care and n 
151 in primary Care); ‡to convert creatinine from mg/dl to mol/l, multiply by 88.4;
§to convert hemoglobin from g/dl to g/l, multiply by 10.
CAD  coronary artery disease; COPD  chronic obstructive lung disease;
creat  creatinine; CVA  cerebrovascular accident; Hb  hemoglobin; EF 
ejection fraction; ETOH  alcohol abuse; MI  myocardial infarction; Na 
sodium; PAD  peripheral arterial disease.
Table 2. Medication Use in Heart Failure Cohort Based on
Provider Type*
Medication†
Cardiology Care
(n  199)
Primary Care
(n  204) p Value
ACE inhibitor 165 (83) 138 (68) 0.001
ARB 18 (8) 9 (4) 0.036
Aspirin 101 (51) 79 (39) 0.015
Beta-blocker 76 (38) 45 (22) 0.001
CCB 54 (27) 40 (20) 0.074
Digoxin 98 (49) 56 (27) 0.001
Diuretics 172 (86) 190 (93) 0.026
Lipid agent 41 (21) 20 (10) 0.002
Warfarin 63 (32) 23 (11) 0.001
*Data are presented as number (percentage); †medications used within six months of
the heart failure diagnosis.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker;
CCB  calcium channel blocker; lipid agent  lipid modifying agent (includes
statins, fibrates, and niacin).
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beta-blockers, and digoxin within six months of the HF
diagnosis. Primary care physicians were more likely to use
diuretics (93% vs. 86%, p  0.26). The use of medications
(within six months of the HF diagnosis) for specific comor-
bid conditions is shown in Table 3. In patients with low EF
(45%), the CC group had a higher use of ACE inhibitors
and beta-blockers within six months of the diagnosis. The
use of lipid-modifying therapy (hydroxymethylglutaryl co-
enzyme A reductase inhibitors, fibric acid derivatives, or
nicotinic acid) was 23% in the CC group versus 15% in the
PC group (p  0.027). Specifically, in patients with
coronary, cerebrovascular, or peripheral arterial disease,
lipid-modifying therapy was higher in the CC group. The
use of aspirin was similar between the CC and PC groups in
this subset of patients. In patients with AF, warfarin use was
higher in the CC group. Finally, patients managed by
cardiologists were more likely to have an investigation for
ischemia or coronary disease by noninvasive stress testing or
cardiac catheterization as a potential cause of their HF (50%
vs. 30%, p  0.001) compared with those managed by PC.
Clinical outcomes. The numbers of primary events (deaths
and cardiovascular hospitalizations) are shown in Table 4.
There was no significant difference between the numbers of
either deaths or hospitalizations. However, when propor-
tional hazards models were constructed that adjusted for the
patient characteristics that differed between the groups and
other variables that had prognostic significance, CC was
associated with a reduction in the primary outcome of time
to death or cardiovascular hospitalization (hazard ratio
(HR) 0.65, 95% confidence interval [CI] 0.45 to 0.96, p 
0.03). Ejection fraction45% (HR 1.77, 95% CI 1.2 to 2.6,
p  0.0052) was the most significant predictor and the only
other independent predictor of outcome in the multivariate
analysis (Table 5). There was a significant interaction
between specialty care and low ejection fraction (p  0.01)
suggesting that the beneficial effect of cardiology care was
driven by a reduction of events in the group of patients with
low ejection fraction. This study was not powered to look at
the effect of CC on cardiovascular hospitalizations and
death separately, but when analyzed in multivariate analysis
there is a trend toward reduced cardiovascular hospitaliza-
tions (HR 0.66, 95% CI 0.4 to 1.0, p  0.05), but not
deaths in the CC group.
DISCUSSION
Principal findings. This study demonstrates several impor-
tant differences between the characteristics, management,
and outcomes of outpatients with new-onset HF treated by
cardiologists and those treated by PC physicians. First,
patients managed by cardiologists differ significantly from
those managed by PC physicians; specifically, they tend to
be younger, more often men, and to have more severe
cardiac dysfunction and more associated cardiac diseases.
The second finding is that guideline recommendations were
more frequently fulfilled in the CC patients. Third, and
most notably, when the results are adjusted for the signifi-
cant differences between patients managed by the two
groups of providers, CC was an independent predictor of a
reduced hazard for the composite outcome of death or
hospital admission for a cardiovascular diagnosis.
Relationship of present findings to prior studies. It is
expected that patients receiving CC have more severe or
more complex heart disease, but the differences in gender
and age may reflect referral bias or a lower propensity to seek
out specialty care among women and older patients. It
should be noted that patients with dementia, terminal
illnesses, and nursing home residence were specifically
excluded from this cohort in order to eliminate patients in
whom guideline recommendations may not have the same
priority and in whom the outpatient physician may have less
control over patient management. Because these patients are
less likely to receive specialty care, these exclusions also serve
to limit the differences between the two provider groups.
Nonetheless, the differences observed in the present study
are consistent with prior studies in patients with HF and
coronary disease (10,12–14,18,19).
Prior studies have also shown that cardiologists adhere
more closely to guidelines than PC physicians, both in HF
and coronary disease patients (4,5,20–22). In the present
study, more CC patients had measurements of left ventric-
ular function and more had assessments for myocardial
ischemia. A higher proportion of CC patients were treated
with ACE inhibitors, and this was specifically the case in
those with documented low EF. Although at the time these
Table 3. Medication Use* Based on Underlying Comorbidity†
Cardiology Primary Care p Value
Low EF (45%) (n  125) (n  66)
ACE inhibitor 114 (91.2) 47 (71.2) 0.001
Beta-blockers 48 (38.4) 14 (21.2) 0.016
CAD (n  126) (n  87)
Aspirin 80 (63.5) 47 (54) 0.17
Beta-blockers 57 (45.2) 28 (32.2) 0.056
Lipid agent 26 (28.6) 14 (16.1) 0.035
PAD/CVD/CAD (n  138) (n  119)
Aspirin 81 (58.7) 58 (48.7) 0.11
Lipid agent 36 (26.1) 14 (11.8) 0.004
Atrial fibrillation (n  51) (n  31)
Warfarin 40 (78.4) 15 (50) 0.008
*Medications used within six months of the heart failure diagnosis; †Data are
presented as number (percentage).
ACE angiotensin-converting enzyme; CAD coronary artery disease; CVD
cerebrovascular disease; EF  ejection fraction; lipid agent  lipid modifying agents
including statins, fibrates, and niacin; PAD  peripheral arterial disease.
Table 4. Unadjusted Deaths and CV Hospitalizations*
Event
Cardiology
(n  199)
Primary Care
(n  204) p Value
CV hospitalization 56 (28) 59 (29) 0.91
Death 21 (11) 27 (13) 0.43
Death and/or CV hospitalization 65 (33) 77 (38) 0.32
*Data are presented as number (percentage).
CV  cardiovascular.
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patients developed HF, the substantial benefit of beta-
blockers in reducing mortality and morbidity in HF patients
was only becoming apparent and the use of beta-blockers
was not widely recommended, it is noteworthy that a higher
proportion of CC patients were receiving a beta-blocker,
despite their lower EFs. Finally, cardiologists were more
likely to use recommended therapies for related coexisting
conditions, such as aspirin and lipid-modifying agents for
CAD, peripheral arterial, and cerebrovascular disease, and
warfarin for AF. It should be noted that although guideline-
recommended treatment rates by cardiologists were rela-
tively higher in this study, the absolute rates were still not
ideal. Other models of care such as HF case management
programs may have resulted in even higher rates of guideline
adherence.
In the case of post-MI patients, improved guideline
adherence has been associated with improved outcomes
in-hospital and during one-year follow-up in several studies
(9,10). In one such study, multivariate analyses suggested
that the greater use of recommended medications and of
early reperfusion strategies explained some, but not all, of
this improvement in outcome (22).
Improved outcomes secondary to specialty care have not
necessarily been the case with HF patients (5,7,14,19). A
number of methodologic challenges may explain the vari-
ability in the previously reported HF study results, which
have generally involved hospitalized patients. In the inpa-
tient setting, specialty consultation and collaborative treat-
ment are common and are often undocumented (“curbside
consultations”) and, therefore, it is often difficult or even
impossible to determine which providers are most respon-
sible for a patient’s management. A focus on hospitalized
patients may be more appropriate for acute conditions such
as MI or unstable angina, but provides a very circumscribed
window into the management and outcomes of patients
with illnesses such as chronic HF, where mortality during a
given admission contributes relatively little to the long-term
outcome and where the management and treating physi-
cians often differ markedly from the in-patient to the
postdischarge period.
There is very little information about differences in
outcomes among HF outpatients managed by cardiologists
and by PC providers, and most reports have focused on
transplant programs and specialized HF clinics. The present
study was designed to minimize several of these confound-
ing factors. Using an HMO population allowed ascertain-
ment of the providers and accurate definition of the provider
groups. In addition, the patients in the CC and PC groups
were more similar than in most studies, most likely because
they were derived from the same HMO pool and access to
specialty care was not restricted. Some conditions often
differentially distributed between patients followed by car-
diology and PC physicians, such as dementia and certain
severe comorbidities, were excluded in advance. The focus
on patients with new-onset HF was a unique feature of the
study. This approach was selected because the identity of
the physicians managing the patients’ HF could be ascer-
tained, whereas in patients with chronic HF, especially
those who have been hospitalized in the past, it is less clear
who may have evaluated the patients and initiated medica-
tions. Furthermore, the initial management of HF patients
may play a critical role in their subsequent natural history
and prognosis, so that the impact of interventions such as
treatment with angiotensin-converting inhibitors and beta-
blockers and differences in the management of coronary
disease may have greater impact on this population.
Study limitations. This was a prospectively designed
study, but the cohorts were identified and the data were
gathered retrospectively. As noted earlier, some patients
were excluded to limit the differences between CC and PC
patients, but significant differences remained, including
older age and more women in the PC group and more
Table 5. Cox Proportional Hazards Analyses for Predicting Death or
Cardiovascular Hospitalization*
Univariate Analysis Multivariate Analysis
HR 95% CI p Value HR 95% CI p Value
Age (per decade) 1.01 0.9–1.2 0.88 1.03 0.9–1.2 0.85
Male 1.10 0.8–1.6 0.57 0.94 0.6–1.4 0.76
Low EF 1.66 1.2–2.3 0.004 1.92 1.3–2.9 0.002
Cardiology care 0.88 0.6–1.2 0.47 0.62 0.4–0.9 0.02
COPD 1.32 0.9–1.9 0.14 1.39 0.9–2.1 0.11
CAD 1.45 1.0–2.1 0.03 1.33 0.9–2.0 0.18
DM 1.30 0.9–1.9 0.16 1.10 0.7–1.7 0.66
PAD 1.84 1.3–2.7 0.002 1.48 0.9–2.4 0.11
SBP (per 10 mm Hg) 0.92 0.9–1.0 0.03 0.94 0.9–1.0 0.07
AF 1.08 0.7–1.6 0.72
Na 135 mmol/l 1.16 0.6–2.2 0.64
Creat 1.4 mg/dl 1.32 0.9–2.0 0.21
Hb11 g/dl 0.79 0.4–1.5 0.45
*Mean follow-up 22 months. Covariates evaluated included age (per decade), atrial fibrillation (AF), chronic obstructive
pulmonary disease (COPD), coronary artery disease (CAD), creatinine (creat), diabetes mellitus (DM), low ejection fraction (EF
45%), gender, hemoglobin (Hb), peripheral arterial disease (PAD), sodium (Na), and systolic blood pressure (SBP) (per 10 mm
Hg increment).
HR  hazard ratio; CI  confidence interval.
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systolic dysfunction, coronary disease, and AF in the CC
group. Although adjustments were performed in the mul-
tivariable analyses, there may have been other unmeasured
confounders, which could account for differences in out-
comes. In addition, differences in medication use were
determined from crude utilization rates based on chart
review and did not account for evidence of prior drug
intolerances or contraindications.
As is the case in clinical practice, many of the patients in
this cohort were seen by both PC providers and cardiolo-
gists. In the PC group, 18% of patients saw a cardiologist at
least once during the follow-up period. The categorization
of such patients into CC or PC groups is of necessity
somewhat arbitrary. The criteria employed in this study
were designed to assure at least moderate participation by a
cardiologist in the CC group, but at the same time to allow
patients to be classified as having CC even if they had only
a small number of visits to cardiologists, as requiring a larger
number or percent of visits would have resulted in prefer-
ential assignment to PC for patients who had early out-
comes. Importantly, the criteria for this classification were
developed before any of the analyses were performed.
Lastly, this study involved new-onset HF patients in a
community outpatient cohort and, therefore, the results may
not be generalizable to other practice settings or patients
later in their disease course.
Conclusions and implications. This study suggests that
participation by cardiologists in the care of patients with
recent-onset HF managed in the outpatient setting is
associated with reduced mortality and morbidity, as dem-
onstrated by a significant reduction in the composite of
death and cardiovascular hospitalization. This is likely to be
due at least in part to better adherence to guideline
recommendations, particularly the greater use of medica-
tions such as ACE inhibitors and beta-blockers, which have
been shown to reduce these adverse outcomes. Additional
research is required to determine whether these results can
be extended to chronic HF in the ambulatory care setting or
to the postdischarge phase of patients hospitalized with HF.
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